Pallas Capital Advisors’s Axsome Therapeutics AXSM Stock Holding History

Pallas Capital Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.86M	Sell	40,610 -3,299	-8%	-$570K	0.26%	73
2025 Q4	$8.02M	Buy	43,909 +4,465	+11%	+$623K	0.26%	72
2025 Q3	$4.79M	Buy	39,444 +1,672	+4%	+$188K	0.18%	97
2025 Q2	$3.94M	Buy	37,772 +2,492	+7%	+$264K	0.15%	111
2025 Q1	$4.11M	Buy	35,280 +8,845	+33%	+$1.01M	0.17%	113
2024 Q4	$2.24M	Buy	+26,435	New	+$2.43M	0.1%	149

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pallas Capital Advisors's AXSM Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Axsome Therapeutics (AXSM) stake by 7.5% in Q1 2026, selling an estimated $570K and leaving 40,610 shares worth $6.86M. The position accounts for 0.26% of the portfolio, ranked #73.

Pallas Capital Advisors first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.02M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Pallas Capital Advisors held 40,610 shares of Axsome Therapeutics worth $6.86M as of Q1 2026.
Pallas Capital Advisors sold 3,299 Axsome Therapeutics shares in Q1 2026, an estimated $570K.
Axsome Therapeutics made up 0.26% of Pallas Capital Advisors's portfolio in Q1 2026, its #73 holding.
Pallas Capital Advisors first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
Pallas Capital Advisors's Axsome Therapeutics position peaked at $8.02M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.